You are here: Industry Insights > Regeneron

News List

Regeneron's COVID-19 Antibody Cocktail Gets EUA contractpharma
November 24, 2020
Expects to have treatment doses ready for approximately 80,000 patients by the end of November, and 200,000 by the first week of January.
US FDA grants EUA to Regeneron’s antibody cocktail for Covid-19 pharmaceutical-technology
November 23, 2020
The US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to Regeneron Pharmaceuticals’ antibody cocktail casirivimab and imdevimab for treating patients with mild to moderate Covid-19.
COVID-19 Outpatient Trial Demonstrates REGN-COV2 Antibody Cocktail Reduced Virus Levels americanpharmaceuticalreview
November 09, 2020
Regeneron Pharmaceuticals announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Regeneron to continue patient recruitment for Covid-19 trial pharmaceutical-technology
November 09, 2020
The independent data monitoring committee (DMC) has recommended the continuation of Regeneron’s UK-based RECOVERY trial analysing REGN-COV2 in hospitalised patients with Covid-19.
IDMC recommends modifications to Regeneron COVID-19 antibody trial europeanpharmaceuticalreview
November 06, 2020
The clinical trial testing the REGN-COV2 antibody cocktail should be altered, according to the Independent Data Monitoring Committee (IDMC).
Regeneron named top biopharma company to work for europeanpharmaceuticalreview
November 04, 2020
According to Regeneron, it has placed either first or second in the same ranking for the past ten years, making it the most highly ranked company of the decade.
FDA approves Regeneron’s Inmazeb for Ebola infection treatment pharmaceutical-technology
October 16, 2020
The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals’ Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) to treat Ebola virus infection in adult and paediatric patients.
Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients worldpharmanews
October 15, 2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in ...
US, AstraZeneca sign pact for COVID-19 antibody treatment used to treat Trump expresspharma
October 12, 2020
The agreement, under Operation Warp Speed, is to develop a monoclonal antibody cocktail that can prevent COVID-19, especially in high-risk population.
FDA Grants Dupixent Breakthrough Therapy Designation for Eosinophilic Esophagitis americanpharmaceuticalreview
September 18, 2020
Regeneron Pharmaceuticals and Sanofi announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Dupixent® (dupilumab) for the treatment of patients 12 years and older with eosinophilic esophagitis (EoE).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page